• Advocacy Masterclass
  • Patient Storybook
0 Items
Patients Rising Now
  • Home
  • About
    • About Us
    • Who We Are
    • Partners and Coalitions
    • Corporate Members
    • Financials
  • News & Insights
  • Positions
    • Legislative Positions
    • Positions
    • Policy Supported
  • Take Action
    • We The Patients Fly-in 2023
    • Patient StoryBook
    • What You Can Do
    • Patient Action Center
    • Advocacy Masterclass
  • Donate
Select Page
  • Home
  • About
    • About Us
    • Who We Are
    • Partners and Coalitions
    • Corporate Members
    • Financials
  • News & Insights
  • Positions
    • Legislative Positions
    • Positions
    • Policy Supported
  • Take Action
    • We The Patients Fly-in 2023
    • Patient StoryBook
    • What You Can Do
    • Patient Action Center
    • Advocacy Masterclass
  • Donate

Patients Rising Now Pens Letter Regarding S.2910: The Expanding Access to Low-Cost Generics Act of 2021

May 16, 2022 | Featured, Letters Submitted | Generic Medicines

We appreciate the work of the Senate Committee on Health, Education, Labor, and Pensions (HELP) in reauthorizing the Food and Drug Administration’s (FDA) user fee programs for generic drugs (GDUFA). The improvements in GDUFA III will speed patient access to safe, effective and more affordable generic medicines, especially complex generics. These improvements are real and measurable and worthy of the Committee’s support and Congress’ swift ratification. 

View/Download Letter

 

 

facebookShare on Facebook
TwitterTweet
FollowFollow us
PinterestSave

Tags: Generic Medicines

Categories

  • Access
  • Advocacy
  • California
  • Comment Letters
  • Copay Accumulators
  • Copay Assistance
  • COVID-19
  • Drug Costs
  • FDA
  • Featured
  • Featured Action
  • Federal Issues
  • Health Insurance
  • Health Policy
  • ICER
  • Illinois
  • Issues
  • Letters Submitted
  • Letters Supported
  • Massachusetts
  • Medicaid
  • Medicare
  • Medicare Part D
  • News
  • Op-Ed
  • Out of Pocket Costs
  • Pharmacy Benefit Managers
  • Podcast
  • Prescription Drugs
  • Press Releases
  • Public Statement
  • QALY
  • State Issues
  • Statements
  • Step Therapy
  • Surprise Billing
  • Uncategorized
  • Value Based Insurance Design
  • Value Frameworks
  • Virtual Advocacy Chat

Tags

21st Century Cures Act 340B Access to Care Advocacy Alzheimer's Biden Administration biosimilars Cancer cms Copay Accumulators copay assistance COVID-19 Vaccine drug costs Drug Manufacturing Drug Pricing drug rebate fail first FDA Gene Therapies H.R.3 Health Insurance hospital bills HR 3708 hsa ICER Insurance design Joe Biden medicare Part B medicare part D Mental Health Nonmedical Switching open enrollment Out of Pocket Costs PBM PBMs pharmacy benefit managers Price Transparency Prior Authorization QALY Rare Disease Right to Repair Step Therapy Telehealth transparency Value Framework

Recent Posts

  • Out-of-the-Box Thinking Needed to Boost Healthcare Professional Workforce, Improve Access 
  • Patient Group Exposes Vision Benefit Manager Abuses in New Campaign
  • Wilcox: A Bipartisan Victory for Patients to Ban Discriminatory Metrics Congressional Subcommittee Agrees: Patient Lives are WORTH IT 
  • Patients Rising Now Submits Comments on Patient Rights to United States Patent and Trademark Office
  • New Harris Poll:  FDA Should Regulate All Medical Device Service and Repair

Get Updates In Your Inbox

Sign up for updates about our patient education, support and advocacy programs and initiatives.

YES, KEEP ME UPDATED

Patients Rising Now

We are a 501c4 group dedicated to demanding transparency in health care.  We are part of the Patients Rising suite of programs and services.

700 12th St. NW 700, Suite 700
Washington, DC 20005
202-679-8223

 

  • Privacy Policy
  • Sponsor Opportunities
  • Patients Rising
  • Patient Action Center
  • Facebook
  • Twitter
  • Instagram
All rights reserved. © 2023 Patients Rising Now